3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Rectal Neoplasms
20
Colonic Neoplasms
20
Carcinoma, Renal Cell
17
Fallopian Tube Neoplasms
15
Breast Neoplasms
13
Ovarian Neoplasms
12
Colorectal Neoplasms
12
Carcinoma, Non-Small-Cell Lung
12
Brain Neoplasms
10
Neoplasms
9
Glioblastoma
9
Brenner Tumor
8
Squamous Cell Carcinoma of Head and Neck
7
Prostatic Neoplasms
7
Pancreatic Neoplasms
7
Melanoma
7
Oligodendroglioma
6
Gliosarcoma
6
Glioma
6
Breast Neoplasms, Male
6
Adenocarcinoma of Lung
6
Lung Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Astrocytoma
5
Adenocarcinoma, Bronchiolo-Alveolar
5
Uterine Cervical Neoplasms
4
Salivary Gland Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Carcinoma, Hepatocellular
4
Unspecified Adult Solid Tumor, Protocol Specific
3
Interventions
Imatinib Mesylate
8
Specimen Handling
2
Oxaliplatin
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
CTLA-4 Antigen
2
temsirolimus
1
rubitecan
1
romidepsin
1
oblimersen
1
motexafin lutetium
1
guadecitabine
1
alvocidib
1
Sorafenib
1
Sirolimus
1
Semaxinib
1
Rogaratinib
1
Nivolumab
1
Leucovorin
1
Irinotecan
1
Immunoglobulin G
1
HhAntag691
1
Floxuridine
1
Erlotinib Hydrochloride
1
Doxorubicin
1
Disulfides
1
Dasatinib
1
Cetuximab
1
Biopsy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NIH
×
Gastrointestinal Stromal Tumors
×
Bevacizumab
×
Clear all
NCT00324987
2017-09-14
S0502
National Cancer Institute (NCI)
Phase 3
Terminated
12 enrolled
13 charts